MRI Analysis in the Growth of Cerebral Aneurysms
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- CHU de Reims
- Trial code
- NCT06705452
- Record updated
- 7 August 2026
- Original description
An intracranial aneurysm is defined as a localized dilatation of the cerebral arteries, which can potentially lead to rupture and subsequent hemorrhagic stroke. The mechanisms by which aneurysms develop and grow remain unknown. The objective of this project is to utilize MRI, a routine non-invasive examination for detecting and following up aneurysms, to identify visually and quantitatively an aneurysm growth and relevant biomarkers that can predict the risk of aneurysm development.Read full original descriptionShow less
4D-MRI Morphological Study of Local Growth in Cerebral Aneurysms
An intracranial aneurysm is defined as a localized dilatation of the cerebral arteries, which can potentially lead to rupture and subsequent hemorrhagic stroke. The mechanisms by which aneurysms develop and grow remain unknown. The objective of this project is to utilize MRI, a routine non-invasive examination for detecting and following up aneurysms, to identify visually and quantitatively an aneurysm growth and relevant biomarkers that can predict the risk of aneurysm development.
Inclusion: Patients with one or more unruptured intracranial aneurysms followed up at the participating center. Patients may have other ruptured and/or treated aneurysms; Patient older than 18 years; Patient consenting to participate to the study; Patient enrolled in the national healthcare insurance program.
Exclusion: Patients who have already received surgical or endovascular treatment for all their aneurysm(s), or who are due to receive such treatment in less than 2 months; Patients with an allergy to one of the contrast agents (Iodixanol, Gadoteric acid); Patients with only ruptured aneurysm(s); Patients with arteriovenous malformations (treated or untreated); Patients with a contraindication to MRI; Pregnant or breast-feeding patients; Patients protected by law.